Exploiting Unique Features of Microneedles to Modulate Immunity

Abstract

Microneedle arrays (MNAs) are small patches containing hundreds of short projections that deliver signals directly to dermal layers without causing pain. These technologies are of special interest for immunotherapy and vaccine delivery because they directly target immune cells concentrated in the skin. The targeting abilities of MNAs result in efficient immune responses—often more protective or therapeutic—compared to conventional needle delivery. MNAs also offer logistical benefits, such as self-administration and transportation without refrigeration. Thus, numerous preclinical and clinical studies are exploring these technologies. Here we discuss the unique advantages of MNA, as well as critical challenges – such as manufacturing and sterility issues – the field faces to enable widespread deployment. We explain how MNA design parameters can be exploited for controlled release of vaccines and immunotherapies, and the application to preclinical models of infection, cancer, autoimmunity, and allergies. We also discuss specific strategies to reduce off-target effects compared to conventional vaccine delivery routes, and novel chemical and manufacturing controls that enable cargo stability in MNAs across flexible intervals and temperatures. We then examine clinical research using MNAs. We conclude with drawbacks of MNAs and the implications, and emerging opportunities to exploit MNAs for immune engineering and clinical use.